Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: A study from the British Society for Blood and Marrow Transplantation

Bone Marrow Transplantation

Volumn 49, Issue 1, 2014, Pages 42-48

  Marsh, J C ^a   Pearce, R M ^b   Koh, M B C ^c   Lim, Z ^d   Pagliuca, A ^a   Mufti, G J ^a   Perry, J ^b   Snowden, J A ^a,e   Vora, A J ^f   Wynn, R T ^g   Russell, N ^h   Gibson, B ⁱ   Gilleece, M ^j   Milligan, D ^k   Veys, P ^l   Samarasinghe, S ^m   McMullin, M ⁿ   Kirkland, K ^b   Cook, G ^j  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d National University Cancer Institute   (Singapore)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^g ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^j ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^k BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^l GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^m Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

ⁿ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

more..

Author keywords

Alemtuzumab; Aplastic anemia; ATG; SCT

Indexed keywords

ALEMTUZUMAB; THYMOCYTE ANTIBODY;

ABDOMINAL BLEEDING; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW; BRONCHIOLITIS; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; EVENT FREE SURVIVAL; GRAFT FAILURE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFECTION; INTERSTITIAL PNEUMONIA; IRRADIATION; MAJOR CLINICAL STUDY; MATCHED SIBLING DONOR; MATCHED UNRELATED DONOR; MISMATCHED UNRELATED DONOR; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; SEVERE APLASTIC ANEMIA; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GREAT BRITAIN; HUMANS; INFANT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891882475     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.115     Document Type: Article

References (36)

1. Armand P, Antin JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant 2007; 13: 505-516.
2. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience. Semin Hematology 2000; 37: 69-80.
3. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
4. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood 1997; 89: 3890-3891.
5. Champlin RE, Perez W, Passweg J, Klein J, Camitta B, Gluckman E et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109: 4582-4585.
6. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
7. Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socie G et al. on behalf of the Severe Aplastic Anaemia Working Party, European Group for Blood and marrow Transplantation. Improving outcome of patients older than 30 years receiving HLA-identical sibling HSCT for severe acquired aplastic anemia using fludarabinebased conditioning: a comparison with conventional conditioning regimen. Haematologica 2009; 94: 1312-1315.
8. Schrezenmeier H, Passweg J, Marsh JCW, Bacigalupo A, Bredeson CN, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400.
9. Bacigalupo A, Socie G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M et al. for the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Bone marrow versus peripheral blood sibling transplants in acquired aplastic anemia: survival advantage for marrow in all age groups. Haematologica 2012; 97: 1142-1148.
10. Maury S, Balere-Appert M, Chir Z, Boiron J, Galambrun C, Yakouben K et al. for the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007; 92: 589-596.
11. Bacigalupo A, Locatelli F, Dini G, Marsh J, Pession A, Socie G et al. for the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation, (SAA WP-EBMT). Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005; 36: 947-950.
12. Bacigalupo A, Socie G, Lanino E, Prete A, Locatelli F, Locasciulli A et al. for the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica 2010; 95: 976-982.
13. Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208-215.
14. Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002; 100: 799-803.
15. Kennedy-Nasser A, Leuknig K, Mahiajan A, Weiss H, Arce J, Gottschalk S et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12: 1277-1284.
16. Yagasaki H, Takahashi Y, Hama A, Kudo K, Nishio N, Muramatsu H et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anaemia. Bone Marrow Transplant 2010; 45: 1508-1513.
17. Deeg H, O'Donnell M, Tolar j, Agarwal R, Harris R, Feig S et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108: 1485-1491.
18. Konopacki J, Porcher R, Robin M, Bieri S, Cayuela JM, Larghero J et al. Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning. Haematologica 2012; 97: 710-716.
19. Passweg JR, Aljurf M. Treatment and hematopoietic SCT in aplastic anemia. Bone Marrow Transplant 2013; 48: 161.
20. Marsh JCW, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. for the British Committee for Standards in Haematology (BCSH). Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43-70.
21. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland R, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351-2357.
22. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48: 63-70.
23. Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood 1987; 70: 1718-1721.
24. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988; 70: 177-182.
25. Lee J-H, Choi S-J, Lee J-H, Lee YS, Seol M, Ryu SG et al. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 2005; 35: 755-761.
26. Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK et al. Successful engraftment with fludarabine, cyclophosphamide and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: a phase II prospective multicenter study. Biol Blood Marrow Transplant 2010; 11: 1582-1588.
27. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers MED, Witherspoon RP et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637-3645.
28. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 103: 2490-2497.
29. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A et al. Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation. Non-malignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373-3385.
30. Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, Storb RF et al. Thyroid function following hematopoeitic cell transplantation in children: 30 years' experience. Blood 2009; 113: 306-308.
31. Sanders JE, Woolfry AE, Carpenter PA, Storer BE, Hoffmeister PA, Deeg HJ et al. Late effects among pediatric patients follwed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 2011; 18: 1421-1428.
32. Samarasinghe S, Steward C, Hiwarkar P, Saif MA, Hough R, Webb D et al. Excellent outcomes of matched unrelated donor transplantation in paediatric aplastic aanemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol 2012; 157: 339-346.
33. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111: 1054-1059.
34. Sangiolo D, Storb R, Deeg HJ, Flowers MED, Martin PJ, Sandmaier BM et al. Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant 2010; 16: 1411-1418.
35. Gupta V, Eapen M, Bajorunaite R, Carreras J, Aljurf M, Gale RP et al. on behalf of the Writing Committee. Impact of age on outcomes after transplantation for acquired aplastic anemia using HLA-identical sibling donors. Haematologica 2010; 95: 2119-2125.
36. Eapen M, Le-Rademacher J, Antin J, Champlin RE, Carreras J, Fay J et al. Effect of stem cell source on outcomes after adult unrelated donor transplantation in severe aplastic anemia. Blood 2011; 118: 2618-2621.